[A20-43] Darolutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 03.08.2020
Commission awarded on 30.04.2020 by the Federal Joint Committee (G-BA).
Adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
Indication of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.